Email this article 
THE PRETREATMENT PROSTATE-SPECIFIC ANTIGEN DOUBLING TIME: CLINICAL AND PROGNOSTIC VALUES IN PATIENTS WITH PROSTATE CANCER
- Authors: Zharinov G.M.1, Bogomolov O.A.1
-
Affiliations:
- Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of the Russian, St. Petersburg
- Issue: Vol 10, No 1 (2014)
- Pages: 44-48
- Section: PROSTATE CANCER
- Published: 30.03.2014
- URL: https://oncourology.abvpress.ru/oncur/article/view/14
- DOI: https://doi.org/10.17650/1726-9776-2014-10-1-44-48
- ID: 14
Cite item
Full Text
Abstract
The purpose of the study – to estimate the clinical and prognostic values of the pretreatment prostate specific antigen (PSA) doubling time (PSADT) in patients with prostate cancer.
Materials and methods. Pretreatment PSADT and follow-up information was compiled on 912 men who were treated with external beam radiation therapy (RT). PSADT were compared with the clinical tumor category, Gleason score, PSA level at diagnosis, as well as the age and level of education of patients. The pretreatment PSADT also were compared with survival rates of patients.
Results. In the current study the correlation between the PSADT and the degree of tumor progression was shown. PSADT decreased with the increase of clinical tumor stage, Gleason score and PSA level at diagnosis. Moreover, in the study the prognostic value of PSADT was confirmed. The statistically and clinically significant associations between the PSADT and all-cause mortality in the setting of PSA failure following have been described.
About the authors
G. M. Zharinov
Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of the Russian, St. Petersburg
Email: urologbogomolov@gmail.com
Russian Federation
O. A. Bogomolov
Russian Research Center of Radiology and Surgical Technologies, Ministry of Health of the Russian, St. Petersburg
Author for correspondence.
Email: urologbogomolov@gmail.com
Russian Federation
References
Supplementary files
